NIKKEI 225
38,527.60 -309.86 (-0.80%) HANG SENG
18,651.08 +206.97 (+1.12%) CRUDE OIL
73.24 -0.01 (-0.01%) GOLD FUTURES
2,351.50 +4.10 (+0.17%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,481.51 +1,407.19 (+2.60%)
Ironwood Pharmaceuticals, Inc. (IRWD)
After hours:
| Previous close | 6.81 |
| Open | 6.78 |
| Bid | 6.48 x 200 |
| Ask | 6.53 x 1100 |
| Day's range | 6.50 - 6.86 |
| 52-week range | 5.76 - 15.70 |
| Volume | |
| Avg. volume | 3,549,503 |
| Market cap | 1.082B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.78 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.83 |
Business WireIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City.
Business WireIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
Simply Wall St.US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
